Disease · MONDO_0005147

type 1 diabetes mellitus

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. type 1 diabetes mellitus. Diseases, record MONDO_0005147. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005147

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: type 1 diabetes mellitus; Open Targets
Open Targets ID: MONDO_0005147; Open Targets
Other names: Autoimmune Diabete, Autoimmune Diabetes, Brittle Diabetes Mellitus, DIABETES MELLITUS TYPE 01, DMI UNSPF NT ST UNCNTRLD, DMI UNSPF UNCNTRLD, Diabete, Autoimmune, Diabetes Mellitus, Brittle, Diabetes Mellitus, Insulin Dependent, Diabetes Mellitus, Juvenile Onset, Diabetes Mellitus, Ketosis Prone, Diabetes Mellitus, Sudden Onset, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type I, Diabetes mellitus type 1 (disorder), Diabetes mellitus type I [insulin dependent type] [IDDM] [juvenile type], not stated as uncontrolled, with unspecified complication, Diabetes mellitus type I [insulin dependent type] [IDDM] [juvenile type], uncontrolled, with unspecified complication, Diabetes, Autoimmune, IDDM, IDDM - Insulin-dependent diabetes mellitus, Insulin dependent diabetes mellitus, Juvenile onset diabetes mellitus, Ketosis-Prone Diabetes Mellitus, Mellitus, Sudden-Onset Diabetes, Sudden-Onset Diabetes Mellitus, T1D, T1DM, diabetes mellitis type 1, diabetes mellitis type I, immune mediated diabetes, insulin dependent diabetes, juvenile diabetes, type 1 diabetes, type I diabetes, type I diabetes mellitus; Open Targets
Disease Ontology: DOID:9744; Disease Ontology
MeSH: D003922; MeSH
NCI Thesaurus: C2986; NCI Thesaurus
Orphanet: ORPHA:243377; Orphanet
Highest stage of its drugs: Approval, for 7 of its 304 drugs, from ClinicalTrials.gov, DailyMed, EMA Human Drugs, FDA and TTD; Open Targets

Drugs304

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
INSULIN GLARGINE	CHEMBL1201497	Protein	Approval	DailyMed	96	90	90	Drugs and targets
INSULIN DETEMIR	CHEMBL2104391	Protein	Approval	DailyMed	55	54	54	Drugs and targets
EMPAGLIFLOZIN	CHEMBL2107830	Small molecule	Approval	TTD	17	16	16	Drugs and targets
TEPLIZUMAB	CHEMBL1743078	Antibody	Approval	EMA Human Drugs, FDA and TTD	18	15	14	Drugs and targets
SOTAGLIFLOZIN	CHEMBL3039507	Small molecule	Approval	EMA Human Drugs, at withdrawal	12	10	10	Drugs and targets
DONISLECEL	CHEMBL4594332	Cell	Approval	ClinicalTrials.gov	3	1	1	Drugs and targets
DASIGLUCAGON HYDROCHLORIDE	CHEMBL4650274	Protein	Approval	FDA	1	0	0	Drugs and targets
CARBAMAZEPINE	CHEMBL108	Small molecule	Preapproval	TTD	1	0	0	Drugs and targets
INSULIN HUMAN	CHEMBL1201631	Protein	Phase 3	ClinicalTrials.gov	157	153	142	Drugs and targets
INSULIN ASPART	CHEMBL1201496	Protein	Phase 3	ClinicalTrials.gov	130	130	126	Drugs and targets

1 to 10 of 304

See all 304 drugs

Targets294

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
INSR	Insulin receptor	14	Insulin receptor agonist	Approval	https://conductscience.org/library/genes/3643	Drugs and targets
GLP1R	Glucagon-like peptide 1 receptor	9	Glucagon-like peptide 1 receptor agonist; Glucagon-like peptide 1 receptor antagonist	Phase 3	https://conductscience.org/library/genes/2740	Drugs and targets
ADRB2	Adrenergic receptor	6	Adrenergic receptor agonist; Adrenergic receptor beta antagonist; Beta-2 adrenergic receptor agonist; Beta-2 adrenergic receptor antagonist	Phase 2	https://conductscience.org/library/genes/154	Drugs and targets
SLC5A2	Sodium/glucose cotransporter 2	6	Sodium/glucose cotransporter 2 inhibitor	Approval	https://conductscience.org/library/genes/6524	Drugs and targets
GCGR	Glucagon receptor	5	Glucagon receptor agonist; Glucagon receptor antagonist; Glucagon receptor inhibitor	Approval	https://conductscience.org/library/genes/2642	Drugs and targets
DPP4	Dipeptidyl peptidase 4	4	Dipeptidyl peptidase IV inhibitor	Phase 3	https://conductscience.org/library/genes/1803	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	4	FK506-binding protein 1A inhibitor	Phase 3	https://conductscience.org/library/genes/2280	Drugs and targets
IL17A	Interleukin-17A	4	Interleukin 17A inhibitor	Phase 2	https://conductscience.org/library/genes/3605	Drugs and targets
PPARG	Peroxisome proliferator-activated receptor gamma	4	Peroxisome proliferator-activated receptor gamma agonist; Peroxisome proliferator-activated receptor gamma partial agonist	Phase 3	https://conductscience.org/library/genes/5468	Drugs and targets
TNF	Tumor necrosis factor	4	TNF-alpha inhibitor	Phase 3	https://conductscience.org/library/genes/7124	Drugs and targets

1 to 10 of 294

See all 294 targets

Trials887

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 30 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00659295	Observational Study to Evaluate the Safety of Levemir® in Diabetes		51,170	2011-08-16	Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2	INSULIN DETEMIR	Its record names the disease	ClinicalTrials.gov
NCT02531035	A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone	Phase 3	1,405	2019-11-19	Type 1 Diabetes Mellitus (T1DM), High Level of Sugar (Glucose) in the Blood	SOTAGLIFLOZIN	Its record names the disease	ClinicalTrials.gov
NCT01836523	The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes	Phase 3	1,398	2017-03-06	Diabetes, Diabetes Mellitus, Type 1	LIRAGLUTIDE	Its record names the disease	ClinicalTrials.gov
NCT03214367	A Study of LY900014 in Participants With Type 1 Diabetes	Phase 3	1,392	2020-05-01	Type 1 Diabetes Mellitus	INSULIN LISPRO	Its record names the disease	ClinicalTrials.gov
NCT00229658	An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes		1,297	2009-06-24	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus	PRAMLINTIDE ACETATE	Its record names the disease	ClinicalTrials.gov
NCT01831765	Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes	Phase 3	1,290	2018-01-23	Diabetes, Diabetes Mellitus, Type 1	INSULIN ASPART	Its record names the disease	ClinicalTrials.gov
NCT01454284	A Study in Participants With Type I Diabetes Mellitus	Phase 3	1,114	2018-04-17	Diabetes Mellitus, Type 1	INSULIN GLARGINE, INSULIN PEGLISPRO	Its record names the disease	ClinicalTrials.gov
NCT02500706	Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes	Phase 3	1,108	2018-08-10	Diabetes, Diabetes Mellitus, Type 1	INSULIN ASPART, INSULIN DEGLUDEC	Its record names the disease	ClinicalTrials.gov
NCT02580591	Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)	Phase 3	977	2018-11-02	Diabetes Mellitus, Type 1	EMPAGLIFLOZIN, INSULIN HUMAN	Its record names the disease	ClinicalTrials.gov
NCT02098395	The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes	Phase 3	835	2016-06-03	Diabetes, Diabetes Mellitus, Type 1	LIRAGLUTIDE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 887

See all 887 trials

Comparisons in its trials260

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Type 1 Diabetes vs Type 2 Diabetes: serious adverse events	130 of 13,529	80 of 37,641	51,170	NCT00659295	Trial comparisons
Sotagliflozin 400 mg vs Placebo: deaths from any cause	1 of 699	0 of 703	1,402	NCT02531035	Trial comparisons
Sotagliflozin 400 mg vs Placebo: serious adverse events	48 of 699	23 of 703	1,402	NCT02531035	Trial comparisons
LY2605541 + Insulin Lispro vs Insulin Glargine + Insulin Lispro: serious adverse events	117 of 663	92 of 449	1,112	NCT01454284	Trial comparisons
Insulin Degludec (IDeg) vs Insulin Glargine (IGlar): serious adverse events	58 of 454	70 of 460	914	NCT02034513	Trial comparisons
500 U/mL Insulin Efsitora Alfa vs 100 U/mL Insulin Degludec: deaths from any cause	0 of 343	1 of 349	692	NCT05463744	Trial comparisons
500 U/mL Insulin Efsitora Alfa vs 100 U/mL Insulin Degludec: serious adverse events	45 of 343	24 of 349	692	NCT05463744	Trial comparisons
HOE901-U300 vs Lantus: deaths from any cause	0 of 320	0 of 318	638	NCT02688933	Trial comparisons
HOE901-U300 vs Lantus: serious adverse events	17 of 320	14 of 318	638	NCT02688933	Trial comparisons
IDeg OD vs IGlar OD: serious adverse events	71 of 472	29 of 154	626	NCT00982228	Trial comparisons

1 to 10 of 260

See all 260 comparisons in its trials

Papers from its trials586

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39518671	RESULT	1	PubMed
39196375	RESULT	1	PubMed
38420944	RESULT	1	PubMed
38379002	RESULT	1	PubMed
38117469	RESULT	1	PubMed
38055252	RESULT	1	PubMed
37880868	RESULT	1	PubMed
37861217	RESULT	1	PubMed
37597378	RESULT	1	PubMed
37482222	RESULT	1	PubMed

1 to 10 of 586

See all 586 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005147

GET https://conductscience.org/api/diseases/v1/MONDO_0005147/drugs?page=2

API reference For AI assistants